Comparison of intratumor and intraluminal temperatures during locoregional deep hyperthermia of pelvic tumors
/in Cervical Cancer, International Publications /von 2007-09-01 / Strahlenther Onkol 2007 Sep;183(9):479-86Weekly systemic cisplatin plus locoregional hyperthermia: an effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area
/in Cervical Cancer, International Publications /von 2007-08-01 / Int J Hyperthermia 2007 Aug;23(5):443-50Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours
/in Cervical Cancer, Dendritic Cells, International Publications /von 2007-06-08 / Vaccine 2007 Aug;25(32):6037-46On verification of hyperthermia treatment planning for cervical carcinoma patients
/in Cervical Cancer, International Publications /von 2007-05-01 / Int J Hyperthermia 2007 May;23(3):303-14Immunological role of dendritic cells in cervical cancer
/in Cervical Cancer, Dendritic Cells, International Publications /von 2007-01-01 / Adv. Exp. Med. Biol. 2007;601:155-62Sensitive detection of human papillomavirus type 16 E7-specific T cells by ELISPOT after multiple in vitro stimulations of CD8+ T cells with peptide-pulsed autologous dendritic cells
/in Cervical Cancer, International Publications /von 2006-10-26 / Mol. Cancer 2006 Oct;5:49[Clinical impact of locoregional hyperthermia in gynecological oncology]
/in Breast Cancer, Cervical Cancer, Hyperthermia, International Publications /von 2006-10-01 / Zentralbl Gynakol 2006 Oct;128(5):255-60Radiochemotherapy combined with regional pelvic hyperthermia induces high response and resectability rates in patients with nonresectable cervical cancer > or =FIGO IIB „bulky“
/in Cervical Cancer, International Publications /von 2006-09-18 / Int. J. Radiat. Oncol. Biol. Phys. 2006 Nov;66(4):1159-67Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer
/in Cervical Cancer, International Publications /von 2006-08-01 / Cancer Res. 2006 Aug;66(15):7678-85IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de